不同剂量瑞舒伐他汀钙对老年不稳定型心绞痛患者临床疗效及血清炎症因子的影响

Effects of different doses of rosuvastatin calcium on clinical efficacy and serum inflammatory factors in elderly patients with unstable angina pectoris

目的观察不同剂量瑞舒伐他汀钙对老年不稳定型心绞痛（UAP）患者的临床疗效及血清炎症因子的影响。方法选取老年不稳定型心绞痛患者80例，按照随机数字表法分为低剂量组和高剂量组，除基础治疗外，低剂量组给予瑞舒伐他汀钙10rag／次，1次／d，高剂量组给予瑞舒伐他汀钙20mg／次，1次／d。治疗3个月后，观察两组患者血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）、三酰甘油（TG）、肿瘤坏死因子-α（TNF—α）、白细胞介素-6（IL-6）炎症因子水平及临床疗效，并行安全性评价。结果治疗3个月后，两组患者的各项血脂水平均有显著下降（P〈0．05），且高剂量组患者治疗后下降水平相比于低剂量组患者有统计学意义（P〈0．05）；两组患者的血清TNF—α、IL-6炎症因子水平均有明显下降，与治疗前比较差异有统计学意义（P〈0．05），但高剂量组患者治疗后较低剂量组炎症因子水平改善明显，差异有统计学意义（P〈0．05）；治疗3个月后，低剂量组患者治疗总有效率为72．5％，高剂量组患者治疗总有效率为87．50％，差异有统计学意义（P〈0．05）；两组患者在治疗过程中，均发生药物不良反应，其中低剂量组共出现3例（7．5％），高剂量组5例（12．5％），差异未见统计学意义（P〉0．05）。结论高剂量的瑞舒伐他汀强化降脂治疗老年UAP具有较好的临床疗效和安全性，并能明显改善血清TNF—α及IL-6炎症水平，具有良好的心血管保护作用。

Objective To observe the effects of different doses of rosuvastatin calcium on the clinical efficacy and serum inflammatory factors of unstable angina pectoris （UAP） patients. Methods Eighty elderly patients with unstable angina were selected, according to random number table, all the patients were randomly divided into low dose group and high dose group. In addition to the foundation treatment, the low dose group were given rosuvastatin calcium 10 mg/time, 1 time/day. The high dose group were given 20 mg each time, 1 time each day. After 3 months of treatment, The levels of serum total cholesterol （TC）, low-density lipoprotein cholesterol （LDL-C）, high density lipoprotein cho- lesterol （HDL-C）, three acyl glycerin （TG）, TNF alpha levels, inflammatory markers, IL-6 and the clinical efficacy of the two groups were observed, and the safety was evaluated. Results Three months after treatment, the levels of blood lipid declined significantly in both groups （ P 〈 0.05 ） , and the diffi- erence of the drops between the two groups was significant （ P 〈 0.05 ）. The serum levels of TNF alpha, IL-6 were significantly lower after treatment than those before treatment （ P 〈 0.05 ）, but the improvement high dose group was more warked after treatment than those of the low dose group, the differences was statistically significant （P 〈 0. 05 ）. Three months after treatment, the total effective rate was 72.5% in low dose group, and the total effective rate was 87.50% in high dose group, there was significant difference （P 〈 0.05 ）. In the process of treatment, there were adverse drug reactions in both groups, with 3 cases （7. 5% ） in low dose group, and 5 cases （ 12.5% ） in high dose group, there was no significant difference in the incidence of adverse reactions between the two groups （P 〉 0. 05 ）. Conclusions High dose of rosuvastatin calcium treatment has clinical effects and safety on elderly UAP, and can markedly improve the serum TNF alpha and IL-6 levels of inflammation, has the good cardiovascular protection.